MeiraGTx announced on April 14, 2026, that it will host a conference call and webcast on April 16 at 8:00 a.m. ET to present long-term follow-up results from the open-label Phase 1 AQUAx study of AAV-hAQP1 for persistent grade 2/3 radiation-induced xerostomia. The presentation will feature patient-reported Xerostomia Questionnaire outcomes, objective unstimulated whole saliva flow rates out to three years across all cohorts and individual patients, investigator commentary on disease burden and patient experience, plus an overview of commercial opportunity and Q&A. This follows the FDA’s Breakthrough Therapy Designation for the program in late March 2026, which was supported by earlier data from the same study. Traders appear to be positioning ahead of potentially confirmatory durability and safety results in a high-unmet-need indication, driving elevated volume and a rapid re-rating of the stock to new 52-week highs. The move aligns with typical biotech catalysts around long-term gene therapy data readouts, especially for programs with recent regulatory designations. No other major company-specific news (e.g., new partnerships, earnings, or regulatory actions) was identified for April 14.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.